Details
| Original language | English |
|---|---|
| Pages (from-to) | 2032-2037 |
| Number of pages | 6 |
| Journal | BIOMATERIALS |
| Volume | 30 |
| Issue number | 11 |
| Early online date | 19 Jan 2009 |
| Publication status | Published - Apr 2009 |
| Externally published | Yes |
Abstract
Reparation of bone defects remains a major clinical and economic concern, with more than 3 million bone grafts performed annually only in the United States and the EU. The search for alternatives to autologous bone grafting led to the approval by the FDA of an absorbable collagen carrier combined with rhBMP-2 for the treatment of certain bone diseases and fractures. The present work is focused on the production of a collagen-targeted rhBMP-2 based system to improve bone formation. We produced a modified rhBMP-2 with only an additional collagen-binding decapeptide derived from the von Willebrand factor and tested its affinity to collagen and its ability to induce ectopic bone formation in vivo when implanted in combination with absorbable collagen sponges or hydroxyapatite. The results showed not only that the rhBMP2-CBD had an increased affinity to collagen, but also that this binding was very stable during a prolonged period of time. In vivo experiments demonstrated that this rhBMP2-CBD maintained its osteoinductive activity, being capable of inducing new bone formation even at lower concentrations than native rhBMP-2. These results indicate that the combination of the fusion protein with absorbable collagen may be a suitable and safer alternative to rhBMP-2 for bone repair purposes.
Keywords
- BMP (bone morphogenetic protein), Bone tissue engineering, Collagen, Osteogenesis, Recombinant protein
ASJC Scopus subject areas
- Chemical Engineering(all)
- Bioengineering
- Materials Science(all)
- Ceramics and Composites
- Biochemistry, Genetics and Molecular Biology(all)
- Biophysics
- Materials Science(all)
- Biomaterials
- Engineering(all)
- Mechanics of Materials
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: BIOMATERIALS, Vol. 30, No. 11, 04.2009, p. 2032-2037.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - The effect of an rhBMP-2 absorbable collagen sponge-targeted system on bone formation in vivo
AU - Visser, Rick
AU - Arrabal, Pilar M.
AU - Becerra, Jose
AU - Rinas, Ursula
AU - Cifuentes, Manuel
N1 - Funding Information: The authors would like to thank Ms. Silvia Hernández and Ms. Eva Jiménez for technical support. Thanks also to Dr. Luis Felipe Vallejo for his valuable help in protein production and refolding. This work was partially supported by Red TerCel RD06/0010/0014 (Ministerio de Sanidad y Consumo), BIO2006-03599 (Ministerio de Educación y Ciencia), TCRM 0012/2006 (Consejería de Salud, Junta de Andalucía) and P07-CVI-02781 (Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía).
PY - 2009/4
Y1 - 2009/4
N2 - Reparation of bone defects remains a major clinical and economic concern, with more than 3 million bone grafts performed annually only in the United States and the EU. The search for alternatives to autologous bone grafting led to the approval by the FDA of an absorbable collagen carrier combined with rhBMP-2 for the treatment of certain bone diseases and fractures. The present work is focused on the production of a collagen-targeted rhBMP-2 based system to improve bone formation. We produced a modified rhBMP-2 with only an additional collagen-binding decapeptide derived from the von Willebrand factor and tested its affinity to collagen and its ability to induce ectopic bone formation in vivo when implanted in combination with absorbable collagen sponges or hydroxyapatite. The results showed not only that the rhBMP2-CBD had an increased affinity to collagen, but also that this binding was very stable during a prolonged period of time. In vivo experiments demonstrated that this rhBMP2-CBD maintained its osteoinductive activity, being capable of inducing new bone formation even at lower concentrations than native rhBMP-2. These results indicate that the combination of the fusion protein with absorbable collagen may be a suitable and safer alternative to rhBMP-2 for bone repair purposes.
AB - Reparation of bone defects remains a major clinical and economic concern, with more than 3 million bone grafts performed annually only in the United States and the EU. The search for alternatives to autologous bone grafting led to the approval by the FDA of an absorbable collagen carrier combined with rhBMP-2 for the treatment of certain bone diseases and fractures. The present work is focused on the production of a collagen-targeted rhBMP-2 based system to improve bone formation. We produced a modified rhBMP-2 with only an additional collagen-binding decapeptide derived from the von Willebrand factor and tested its affinity to collagen and its ability to induce ectopic bone formation in vivo when implanted in combination with absorbable collagen sponges or hydroxyapatite. The results showed not only that the rhBMP2-CBD had an increased affinity to collagen, but also that this binding was very stable during a prolonged period of time. In vivo experiments demonstrated that this rhBMP2-CBD maintained its osteoinductive activity, being capable of inducing new bone formation even at lower concentrations than native rhBMP-2. These results indicate that the combination of the fusion protein with absorbable collagen may be a suitable and safer alternative to rhBMP-2 for bone repair purposes.
KW - BMP (bone morphogenetic protein)
KW - Bone tissue engineering
KW - Collagen
KW - Osteogenesis
KW - Recombinant protein
UR - http://www.scopus.com/inward/record.url?scp=59849120814&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2008.12.046
DO - 10.1016/j.biomaterials.2008.12.046
M3 - Article
C2 - 19155065
AN - SCOPUS:59849120814
VL - 30
SP - 2032
EP - 2037
JO - BIOMATERIALS
JF - BIOMATERIALS
SN - 0142-9612
IS - 11
ER -